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E-mail: barry.clinch@roche.comOseltamivir was the ﬁrst orally active, direct-acting antiviral
developed for inﬂuenza and was generated through a process of
rational drug design [1]. Oseltamivir is indicated for the treat-
ment and prophylaxis of inﬂuenza [2,3], and extensive clinical
data support its efﬁcacy and safety [4–12]. It is the standard of
care for treatment of seasonal inﬂuenza [13,14], forms the
backbone of many national pandemic preparedness plans
[15,16] and has also been included on the World Health Or-
ganization essential medicines list since 2009 [17].
To support the registration of oseltamivir, an extensive
clinical trial programme was conducted by Roche, primarily
between 1997 and 2002. It was ﬁrst approved in Switzerland in
1999 and is currently approved in over 100 countries world-
wide. Since the initial approval, Roche has continued to conduct
supplementary studies to expand the body of evidence sup-
porting oseltamivir’s clinical efﬁcacy and safety. These studies
have, for example, supported the introduction of a paediatric
suspension, and a recent marketing authorization application to
extend the treatment indication to infants younger than 1 year
(approved in the United States). Studies to monitor cases of
resistance are also ongoing.
All of these studies were conducted to the highest regulatory
standards of the time, and the studies that supported the initial
registration were subject to audit by Roche’s quality assurance
department and the US Food and Drug Administration. The
data and reports provided by Roche to health authorities have
always been in full accordance with the speciﬁc requirements of
each country where we have sought a license. Clinical data
from Roche-sponsored and -supported studies have been
published in peer-reviewed journals, starting with the two
pivotal adult oseltamivir treatment studies, which were pub-
lished in 2000 [4,5]. Over the next 14 years, additional data
were published for a variety of indications in different patient
groups, including a pivotal paediatric trial [6], postexposure
prophylaxis [7,8], children with asthma [9], seasonalMicrobiol Infect 2015; 21: 226–229
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p://dx.doi.org/10.1016/j.cmi.2015.01.014prophylaxis in immunocompromised patients [10], resistance
surveillance [11], and treatment for infants [12], elderly and
chronically ill patients [18,19].
As evidenced by our actions, Roche ﬁrmly believes in the
dissemination of data to the scientiﬁc and medical communities.
In recent years attitudes towards sharing clinical trial data have
gradually changed among patients, governments and regulators.
Roche has responded to these changes; summary data and
protocols for all 77 Roche-sponsored oseltamivir studies can
now be accessed online (www.roche-trials.com). Any investi-
gator wishing to analyse individual patient data (IPD) or to
receive clinical study reports (CSRs) can apply for access
(www.clinicalstudydatarequest.com). As part of the process to
access IPD, the investigator is asked to submit a research
proposal for review by an independent panel, which will
consider a number of factors such as the scientiﬁc value of the
question posed, whether available data can support the pro-
posed analysis and the investigators’ qualiﬁcations and experi-
ence to conduct the research.
The changes that have led the scientiﬁc community to this
point have developed over many years, and this debate is by no
means complete. Indeed, among both patients and physicians
there is still a substantial degree of caution around the mecha-
nisms and privacymeasures in place for sharingmedical data [20].
However, Roche believes that enough progress had been made,
and that the advances in technology are sufﬁcient, to allow
greater sharing of data in a manner conducive to high-quality
research while protecting the integrity of the valuable relation-
ship we have with patients who participate in our clinical trials.
The request that Roche received from the Cochrane Acute
Respiratory Infections (ARI) Group in 2009 should be viewed
against this context, since it was unprecedented in a number of
ways:
 A large amount of clinical data was requested, including IPD,
which were not typically provided to non-statutory bodies
at that time.
 The primary stakeholder with whom Roche data is shared
was, and continues to be, regulatory authorities. This was
the only type of data sharing envisaged by the consentious Diseases. Published by Elsevier Ltd. All rights reserved
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clinical study.
 Requiring such detailed data was also a departure for the
Cochrane Collaboration, who typically analysed summary
data only.
Nonetheless, recent experience with the Cochrane
Collaboration and oseltamivir has helped to shape the current
Roche Global Policy on Sharing of Clinical Trials Data [21],
which was implemented in June 2013 and is at the forefront of
the data sharing movement. Roche believes that data from
clinical trials should be made available to both physicians and
patients to help them make the most informed decision
possible when choosing between treatment options. This
should apply to both clinical studies sponsored by pharma-
ceutical companies as well as those conducted by academic
institutions and governments. In fact, sharing clinical trial data
could enhance the trust that patients who enrol in studies have
in companies such as Roche.Sharing clinical study reports with the
Cochrane Acute Respiratory Infections
GroupWith the establishment of the data sharing policy, Roche star-
ted to work towards meeting the Cochrane ARI Group’s
request for access to full CSRs, including IPD. Each individual
CSR had to be redacted to remove patient identiﬁers, such as
demographic or geographical information, as well as the names
and contact details of investigators, vendors and Roche staff. As
this was a lengthy process, CSRs were delivered in batches
between June and November 2013.
Results from the Cochrane ARI Group’s analysis of oselta-
mivir clinical trial data were published in April 2014 [22], and
despite their request for IPD, they did not make use of it. Roche
disputes the ﬁndings and conclusions of this revised report.
Some of the issues have been brieﬂy touched upon in the Roche
response published in the British Medical Journal [23], and a
detailed 70-page critique of their review has been published on
the Cochrane Editorial Unit website (http://editorial-unit.
cochrane.org/cochrane-review-neuraminidase-inhibitors-
inﬂuenza) [24]. To brieﬂy summarize some key topics covered
in this critique, problems with the Cochrane ARI Group’s re-
view include: application of ﬂawed methodology to the
assessment of the symptom alleviation data; misrepresentation
of the clinical value of prophylaxis; consideration of safety data
from only a subset of the studies that were provided; and
inappropriate analysis of these safety data [24]. Roche wel-
comes the constructive interaction we have been able to haveClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologywith the Cochrane editorial unit and are pleased that they have
agreed to host our critique on their website.
In addition to the speciﬁc shortcomings of the Cochrane
ARI Group’s review, the Cochrane Collaboration’s approach
of restricting analyses to randomized controlled trials (RCTs)
means that valuable data from other sources were not
considered. Extensive safety data, collected during 15 years of
oseltamivir use, were not taken into account in this review;
nor were the abundance of observational data, including those
generated during the 2009–2010 inﬂuenza pandemic, which
repeatedly show the clinical beneﬁts of oseltamivir and build
on the ﬁndings of the RCTs. One example is the impact of
oseltamivir on secondary complications of inﬂuenza infection.
Analyses of data from RCTs conducted by several different
groups have consistently found evidence of an effect: the
primary analysis by Jefferson et al. [22] showed a reduction in
the incidence of pneumonia, and the meta-analyses by Kaiser
et al. [25], Hernán and Lipsitch [26] and Ebell et al. [27] all
found a reduction in lower respiratory tract complications
requiring antibiotics. These analyses were in settings where
complication rates are not particularly high, but they predict
that at a population level or in the case of more severe dis-
ease, e.g. during a pandemic, similar reductions would be
observed. Indeed, as far back as 1969, Wingﬁeld et al. [28]
reported the effect of an adamantine drug on inﬂuenza and
hypothesized about the beneﬁt antivirals could bring to
reducing secondary complication rates. Understanding of the
biologic relationship between viral infection and secondary
bacterial infections has grown since then, but it still points
towards that same hypothesis [29–31], and indeed observa-
tional data supports this [32–34]. The combined data sets of
the RCTs and the observational studies form a coherent
whole, and it is entirely appropriate to consider them
together. It is likely that any future inﬂuenza antiviral therapy
would rely on a similar combination of RCT and observational
or real-world data to understand the full spectrum of its
beneﬁts.
Roche considers that the inconsistent and inaccurate analysis
methods used by the Cochrane ARI Group, as detailed previ-
ously [24], as well as the analysis’s exclusion of two major
sources of data, have resulted in inappropriate conclusions
being drawn regarding the efﬁcacy and safety of an established
inﬂuenza medicine. These conclusions risk causing confusion
among patients and physicians and could lead to public health
concerns if patients do not comply with their prescribed
medicine. In this context, it is important to note that use of
oseltamivir for the treatment of inﬂuenza continues to be
endorsed by the US and European Centers for Disease Control
and Prevention (CDC and ECDC), Public Health England, the
Infectious Diseases Society of America and others [35–38].and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 226–229
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oseltamivir data seem to have developed into something far
removed from the initial request from the Cochrane ARI
Group, as highlighted by their call to boycott all Roche medi-
cines [39]. Taking into account the nature and content of all the
supplementary articles and letters from the Cochrane ARI
Group that have been published, it is also difﬁcult to regard
their review as truly independent and balanced. Roche believes
that a fair, transparent and independent approach is required to
address this issue, one that takes into account the views of
others besides those of Roche and the Cochrane
Collaboration.Sharing our data with the Multiparty Group
for Advice on Science (MUGAS)In parallel to sharing CSRs with the Cochrane ARI Group,
Roche also sought a group of independent inﬂuenza experts
who would be willing to review and reanalyse the oseltamivir
data. The founding members of MUGAS, each world-
renowned experts in different aspects of inﬂuenza, were
willing to take on this role and to provide a counterpoint to
the Cochrane ARI Group. Roche provided MUGAS with an
unrestricted grant that allowed them to contract other ex-
perts and institutions in order to carry out the work. In
addition, MUGAS signed a data-sharing agreement with
Roche; as a result, Roche was able to provide MUGAS with
everything that they required for the analysis, using a data
room model similar to that now hosted online (www.
clinicalstudydatarequest.com). Roche played no part in the
design of the analysis plan, selection of studies, conduct or
reporting of the analysis. MUGAS’s preliminary ﬁndings were
presented at the 5th European Scientiﬁc Working Group on
Inﬂuenza conference in Riga, Latvia, in 2014, and a paper with
full details of their work has been published [40]. Roche sees
the ﬁndings of MUGAS’s careful re-analysis as adding an
important independent viewpoint to this discussion.ConclusionRoche has absolute conﬁdence in the quality and integrity of
the data generated for oseltamivir. Oseltamivir continues to
be the cornerstone of inﬂuenza antiviral treatment globally
and has played an important role in the clinical management
of seasonal and pandemic inﬂuenza over the years since it
was ﬁrst introduced. Against that backdrop, another debate
on data sharing emerged. While Roche stands by theClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectdecisions that were made in the past, we are and will be
among the ﬁrst to adopt changes when it best serves patients
and has support from our stakeholders. This outlook means
that Roche now have an industry-leading data-sharing policy
[21]. Speciﬁcally for oseltamivir, this meant that we could
meet the request of the Cochrane ARI Group; however, in
this instance, Roche completely disputes the outcomes of
their analysis. Roche welcomes, and will continue to support,
good-quality third-party research, but it is important that all
parties adopt a transparent and collaborative approach so
that data are handled appropriately and can be discussed
openly.Transparency declarationBoth authors are employees of Roche and hold share options.References[1] Lew W, Chen X, Kim CU. Discovery and development of GS 4104
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